(lp0
S'ARCA biopharma, Inc.  Files An 8-K Results of Operations and ... Market Exclusive - Mar 21, 2017 ARCA biopharma, Inc.  is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases.ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides ... - Business Wire '
p1
aS"Arca Biopharma Inc  Announces The Enrollment Of The Randomized ... Journal Transcript - Mar 8, 2017 Arca Biopharma Inc , announced that 175 patients have been randomized into GENETIC-AF. It's a unique design Phase 2B/3 clinical trial for the evaluation of a new drug - Gencaro (bucindolol hydrochloride, a beta blocker and a mild&nbsp;..."
p2
aS'Ticker Watch: Technical Views on Shares of ARCA Biopharma Inc  Rives Journal - Mar 21, 2017 ARCA Biopharma Inc  currently has a 14-day Commodity Channel Index  of 48.94. Despite the name, CCI can be used on other investment tools such as stocks.'
p3
aS'Arca Biopharma Inc  Announces 175th Patient Randomized into the ... Journal Transcript - Mar 7, 2017 Arca Biopharma Inc , a biopharmaceutical company that develops genetically-oriented therapies meant for treatment of cardiovascular diseases has announced randomizing the GENETIC-AF.ARCA Biopharma, Inc.  Broker Price Targets For The Coming Week - Fiscal Standard'
p4
aS'Why Arca Biopharma Is A Buy Seeking Alpha - Jan 14, 2014 Arca Biopharma  is a pre-revenue company that has patents through 2029 covering the drug Gencaro .'
p5
aS'Stock Review &amp; Consensus Look at Capnia, Inc.  ARCA biopharma ... Rives Journal - Mar 21, 2017 Sell-side analysts are offering a consensus Buy rating on shares of Capnia, Inc. . Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 2.00.'
p6
aS'Interview with the COO: ARCA biopharma, Inc.  The Wall Street Transcript - Mar 10, 2017 Thomas A. Keuer is Chief Operating Officer of ARCA biopharma, Inc. Mr. Keuer was appointed to his current position as Chief Operating Officer in December 2014.'
p7
aS'Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire  - Jan 18, 2017 WESTMINSTER, Colo.----ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the&nbsp;...'
p8
aS'ARCA biopharma, Inc.  Files An 8-K Departure of Directors or ... Market Exclusive - Feb 21, 2017 ARCA biopharma, Inc.  Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.'
p9
aS'ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B ... Yahoo Finance - Mar 6, 2017 ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 175th patient has been randomized into GENETIC-AF,&nbsp;...'
p10
a.